Skip to main content
    V

    Verrica Pharmaceuticals Inc (VRCA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.83
    +0.25 (+6.98%)

    Market Cap: $65.80M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(20/33)
    Avg Surprise
    +13.15%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.52
    Range$-0.57 - $-0.47
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.43-21.9%
    60d ago$-0.43-21.9%
    30d ago$-0.520.0%
    7d ago$-0.520.0%
    Current$-0.52
    Revenue Consensus
    $6M
    Range$5M - $8M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.39
    Range$-0.47 - $-0.26
    4 analysts
    Revenue Consensus
    $8M
    Range$6M - $10M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.39---
    Sep 26EST
    		-$-0.52---
    Jun 26
    Reported Aug 6
    		$-0.54$-0.47-14.89%Miss-316.0%
    Mar 26
    Reported May 12
    		$-0.45$-0.59+22.98%Beat+54.6%
    Dec 25
    Reported Mar 11
    		$-0.51$-0.64+20.31%Beat-153.4%
    Sep 25
    Reported Nov 14
    		$-0.03$-0.06+50.00%Beat+99.4%
    Jun 25
    Reported Aug 12
    		$0.25N/A+130.12%Beat+106.8%
    Mar 25
    Reported May 13
    		$-1.00$-1.36+26.47%Beat+77.3%
    Dec 24
    Reported Mar 11
    		$-0.20$-0.24+16.82%Beat+62.0%
    Sep 24
    Reported Nov 4
    		$-4.90$-3.87-26.61%Miss+9.3%
    Jun 24
    Reported Aug 14
    		$-3.70$-4.02+7.96%Beat-54.2%
    Mar 24
    Reported May 13
    		$-4.40$-4.40+0.00%Beat-193.3%
    Dec 23
    Reported Feb 29
    		$-0.53$-0.53+0.00%Beat-278.6%
    Sep 23
    Reported Nov 9
    		$-5.40$-3.90-38.46%Miss-1688.2%
    Jun 23
    Reported Aug 8
    		$-2.40$-2.00-20.00%Miss+35.1%
    Mar 23
    Reported May 9
    		$-1.50$-1.70+11.76%Beat+51.6%
    Dec 22
    Reported Mar 6
    		$-0.14$-0.19+26.32%Beat+60.0%
    Sep 22
    Reported Nov 7
    		$0.34N/A+134.00%Beat+107.2%
    Jun 22
    Reported Aug 11
    		$-3.70$-3.20-15.63%Miss+14.0%
    Mar 22
    Reported May 9
    		$-3.10$-4.47+30.65%Beat-675.0%
    Dec 21
    Reported Mar 2
    		$-0.35$-0.50+30.00%Beat+32.7%
    Sep 21
    Reported Nov 12
    		$-4.70$-5.10+7.84%Beat-11.9%
    Jun 21
    Reported Aug 10
    		$-4.30$-4.07-5.65%Miss-13.2%
    Mar 21
    Reported May 7
    		$-0.40N/A+88.34%Beat-2.6%
    Dec 20
    Reported Mar 4
    		$-0.52$-0.42-23.81%Miss+83.2%
    Sep 20
    Reported Nov 9
    		$-4.20$-4.33+3.00%Beat-75.0%
    Jun 20
    Reported Aug 5
    		$-3.80$-4.60+17.39%Beat-35.7%
    Mar 20
    Reported May 7
    		$-0.39$-0.38-2.63%Miss+87.0%
    Dec 19
    Reported Mar 13
    		$-3.10$-2.95-5.08%Miss-933.3%
    Sep 19
    Reported Nov 6
    		$-2.40$-2.70+11.11%Beat+11.1%
    Jun 19
    Reported Aug 7
    		$-2.80$-3.40+17.65%Beat+45.1%
    Mar 19
    Reported May 7
    		$-3.00$-2.85-5.26%Miss-3650.0%
    Dec 18
    Reported Mar 7
    		$-0.30$-0.27-11.11%Miss-66.7%
    Sep 18
    Reported Nov 7
    		$-2.70$-2.50-8.00%Miss-13400.0%
    Jun 18
    Reported Aug 7
    		$-5.10$-3.60-41.67%Miss-
    Mar 18
    Reported Jun 15
    		$-0.08$0.00N/AMiss-
    Dec 17
    Reported Mar 30
    		$-0.18$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.02$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.50EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-102.80%Operating Margin-194.50%
    ROE-240.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-5.05x
    Current Ratio1.45xQuick Ratio1.33x
    Trading Statistics
    Beta1.61Avg Volume49.29K
    52-Week High$9.8252-Week Low$3.28

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.13
    SMA 20$4.34
    SMA 50$4.77
    SMA 200$5.89
    EMA 10$4.08
    EMA 20$4.30
    EMA 50$4.72
    EMA 200$5.49

    MACD

    Line: -0.27Signal: -0.22Hist: -0.05

    ADX

    ADX: 13.5+DI: 11.4-DI: 22.8

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$4.57

    Bollinger Bands

    Upper Band$4.95
    Lower Band$3.73
    %B Position2805%(Upper)
    Band Width0.08

    RSI (14-Day)

    Neutral
    35.8

    Momentum Oscillators

    Stoch %K9.0
    Stoch %D6.5
    Williams %R-78.6
    ROC (10d)-20.1%
    Momentum-0.96
    CCI (20d)-185.3
    MFI (14d)21.7

    Volatility Measures

    ATR (14d)$0.36(9.3%)
    StdDev (20d)0.30
    Hist Vol72.7%(High)

    Volume Flow

    VWAP$3.75
    OBV13.2M
    AD Line4.4B
    CMF (20d)-0.510

    Volume Metrics

    Avg Vol (20d)49.5K
    Vol Ratio1.1x
    VWMA (20d)$4.31

    Pivot Points

    R3$5.01
    R2$4.69
    R1$4.14
    Pivot Point$3.82
    S1$3.27
    S2$2.95
    S3$2.40

    Advanced Oscillators

    TSI-26.26
    Ultimate Osc28.2
    KST-144.74

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$5.86M$5.02M$5.09M$14.34M$12.70M$3.44M$344,000$-1,781,000$5.18M$3.83M$1.99M$2.92M
    Cost of Revenue$435,000$544,000$675,000$754,000$340,000$423,000$596,000$351,000$360,000$546,000$144,000$145,000
    Gross Profit$5.43M$4.48M$4.42M$13.59M$12.36M$3.02M$-252,000$-2,132,000$4.82M$3.28M$1.84M$2.77M
    Operating Expenses$18.52M$14.19M$11.61M$11.96M$10.85M$11.15M$11.16M$18.57M$20.02M$21.88M$24.98M$26.69M
    R&D$6.03M$3.86M$2.52M$2.21M$1.85M$2.28M$1.17M$2.40M$3.32M$4.95M$5.32M$6.51M
    SG&A$10.35M$9.99M$8.12M$9.40M$8.85M$8.85M$9.88M$16.08M$16.52M$16.34M$17.00M$20.05M
    Operating Income$-13,097,000$-9,715,000$-7,192,000$1.63M$1.51M$-8,130,000$-11,410,000$-20,704,000$-15,206,000$-18,599,000$-23,137,000$-23,917,000
    Interest Income$111,000$201,000$205,000$159,000$228,000$337,000$205,000$221,000$393,000$598,000$792,000$822,000
    Interest Expense$164,000$160,000$2.85M$2.09M$2.13M$2.20M$2.35M$2.38M$2.37M$2.32M$2.31M$1.66M
    Income Before Tax$-13,153,000$-9,682,000$-8,074,000$-274,000$204,000$-9,742,000$-16,202,000$-22,860,000$-17,186,000$-20,331,000$-24,600,000$-24,802,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-13,153,000$-9,682,000$-8,074,000$-274,000$204,000$-9,742,000$-16,202,000$-22,860,000$-17,186,000$-20,331,000$-24,614,000$-24,802,000
    EBITDA$-12,893,000$-9,529,000$-5,242,000$1.84M$2.31M$-7,668,000$-13,805,000$-20,363,000$-14,877,000$-18,270,000$-22,870,000$-23,757,000
    EBIT$-13,100,000$-9,723,000$-5,432,000$1.66M$2.11M$-7,876,000$-14,058,000$-20,705,000$-15,211,000$-18,610,000$-23,087,000$-23,967,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VRCA

    News

    Lake Street keeps Buy rating for Verrica Pharmaceuticals stock

    Lake Street has reiterated its Buy rating for Verrica Pharmaceuticals (VRCA) stock, setting a price target of USD 9.00. This comes after Verrica presented clinical data for YCANTH showing a 60.1% clearance rate by Day 84...

    ad-hoc-news.de•10/15/26•Bullish

    Verrica Pharmaceuticals Q2FY26 Results: Revenue $5.9M, Net loss $13.2M

    Verrica Pharmaceuticals reported Q2FY26 total revenue of $5.9 million and a GAAP net loss of $13.2 million. While U.S. YCANTH net product revenue grew sequentially...

    scanx.trade•10/14/26•Neutral

    Verrica Pharmaceuticals Q2 2026 Earnings Call Transcript

    Verrica Pharmaceuticals reported Q2 2026 revenue of $5.9 million, driven by a 28% increase in YCANTH dispensed units. The company secured up to $27.5 million in non-dilutive financing from its largest investor...

    Benzinga•10/14/26•Bullish

    Q2 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript

    Verrica Pharmaceuticals Inc. (VRCA) reported a 28% quarter-over-quarter increase in YCANTH applicator units and secured a $27.5 million credit facility...

    GuruFocus•10/8/26•Neutral

    Verrica Pharmaceuticals stock gets a Buy rating from Lake Street

    Lake Street has maintained its Buy rating on Verrica Pharmaceuticals (VRCA) after the company reported its second-quarter 2026 results. Despite a year-over-year revenue decline due to an $8 million milestone in Q2 2025...

    AD HOC NEWS•10/7/26•Somewhat-Bullish

    VRCA Valuation and Fair Value

    P/E
    -2.5x
    P/B
    18.9x
    See GNG's fair value

    VRCA Profitability: Margins, ROIC and FCF

    Gross margin
    92.1%
    Operating margin
    -194.5%
    Net margin
    -102.8%
    ROE
    -240.4%
    FCF margin
    -44.0%

    VRCA Competitors

    CompanyTicker
    XBiotech IncXBIT
    Rein Therapeutics IncRNTX
    Neumora Therapeutics, Inc.NMRA
    OS Therapies IncorporatedOSTX
    Champions Oncology IncCSBR
    ImmunoPrecise Antibodies Ltd.HYFT
    Spero Therapeutics IncSPRO
    MDxHealth SAMDXH

    Sector: Healthcare

    VRCA Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    0
    Buy
    6
    Hold
    1
    Sell
    0
    Strong Sell
    0

    VRCA Bull Case vs Bear Case

    Bull case

    • VRCA beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 85.7% of VRCA's analyst ratings are Buy or Strong Buy.

    Bear case

    • VRCA has a -102.8% net profit margin.
    • VRCA's quarterly revenue changed -53.9% year over year.

    VRCA Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    28.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.52
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About VRCA

    Does VRCA pay dividends?

    Verrica Pharmaceuticals Inc (VRCA) does not currently pay a regular dividend.

    What is VRCA's market cap?

    Verrica Pharmaceuticals Inc (VRCA) has a market capitalization of $65.80M with a current stock price of $3.83.

    Related stocks

    Sector: Healthcare

    All stocks starting with V

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In